
ABOUT SK PHARMTECO
At SK pharmteco our mission is to build strong relationships that create happiness for our customers through the shared goal of producing and delivering life-changing therapies that improve patient outcomes and save lives. With our network of seven global, cutting-edge, facilities our capabilities cover the entire product lifecycle, from initial development to commercial manufacturing. We work with customers in a flexible ‘One Team’ approach, prioritizing collaboration, transparency, and trust to make every interaction easy and seamless.
SK pharmteco offers CDMO services for small molecule, Cell and Gene therapy, and Analytical testing, contact our experts to learn more!
CONTACT INFORMATION
SK pharmteco
12460 Akron St #100
Rancho Cordova, CA 95742
Contact: Liza Rivera
SMALL MOLECULE
-
SK pharmteco's Texas Facility: A Pillar Of Innovation, Sustainability, And Pharmaceutical Excellence
Discover how SK pharmteco's innovative La Porte, Texas facility combines advanced technology, sustainability, and strategic efficiency to redefine excellence in pharmaceutical manufacturing.
-
Energetic And Specialty Chemistry Solutions
Partner with SK pharmteco to harness decades of expertise in safe, scalable, and reliable production of APIs using advanced energetic chemistry, delivering exceptional value from development to commercialization.
-
Demystifying Large Scale Continuous Chromatography For Small Molecules
Learn the fundamentals of developing a continuous chromatography process with Simulated Moving Bed (SMB) technology for small molecules, from gram-scale to multi-ton commercial production.
-
Continuous Flow Processing: A Sustainable Manufacturing Solution
Optimize your manufacturing processes and enhance sustainability, while meeting regulatory requirements and minimizing environmental impact.
-
Third Principle Of Green Chemistry: Less Hazardous Chemical Syntheses
Chemists and chemical engineers must prioritize sustainable practices by innovating holistic, efficient processes that minimize environmental impact and toxicity, addressing challenges like solvent waste and complex molecule synthesis.
-
Empowering API Manufacturing: Perspectives From A CDMO
This presentation delves into the critical implications for CDMOs, exploring actionable strategies to bolster API manufacturing capabilities, improve global competitiveness, and support the resilience of European healthcare systems.
-
Chromatography Solutions
Whether your project requires small-scale optimization or large-scale production, SK pharmteco’s expertise ensures precision, reliability, and efficiency at every step of the process.
-
Partnering Through Membership For A Better Pharmaceutical Industry
Explore our series on key industry advocacy groups to learn how organizations like California Life Sciences (CLS) are driving innovation, fostering growth, and improving patient access in healthcare.
-
SK pharmteco Capacity Update October 2024: Small Molecule
Witness how our 80 years of industry experience and a global capacity of ~1,000 m³ can provide scalable, high-quality solutions to support your small molecule programs.
-
Technology Solutions
At SK pharmteco, we provide our customers with innovative technology-driven solutions for a reduced time-to-market
CELL & GENE THERAPY
-
Revolutionizing Plasmid Design With Trusted Expertise
Optimize your plasmid design to enhance performance, simplify scale-up, and meet your development goals with confidence.
-
Overcoming Plasmid Design Challenges With Expert Support
Learn how strategic plasmid design and specialized consulting services can help overcome engineering challenges and accelerate therapeutic innovation.
-
Transforming Viral Vector Manufacturing With Next-Generation CGMP Plasmids Platform
Watch as experts explore key innovations in plasmid design and production, highlighting how these advancements can directly enhance biomanufacturing workflows.
-
CGMP-Validated RCL Assay Used For Release Testing Of Manufactured Viruses, Gene Mediated Cell Therapy Products
Ensure the safety and efficacy of lentiviral-based therapies by addressing the risks of replication-competent lentiviruses (RCLs) through advanced monitoring and control strategies.
-
cGMP-Ready Clonal HEK293 Cell Line For AAV, Lentiviral, And Adenoviral Vector Production
See how this advanced SKPT-HEK293 4G9 was able to provide a robust, CGMP-ready solution for efficient viral vector production, supporting a range of AAV serotypes and CAR-T Lenti-viral vectors for scalable manufacturing.
-
SK pharmteco Capacity Update October 2024: Cell & Gene Therapy
Check out our enhanced capacity and expertise in supporting CGT projects, offering end-to-end solutions from viral vector and plasmid development to GMP manufacturing and regulatory support.
-
Cell And Gene Therapy Services
Fast-track your cell and gene therapies from cutting-edge process development to commercial success with advanced viral vector manufacturing solutions.
-
Advancing Viral Vector Manufacturing: The Importance Of The Cell Line
Explore the pivotal role of cell lines in viral vector manufacturing, a complex, multi-step process that has traditionally been both time-consuming and labor-intensive.
-
A Platform Approach To Accelerating Advanced Therapy Development And Manufacturing
Explore strategies for integrating cutting-edge technologies and optimizing unit operations to expedite the development and manufacturing of cell and gene therapies.
-
Development Of A Universal, GMP-Ready, Clonal HEK293 Cell Line
When manufacturing adeno-associated virus, lenti- and adenoviral vectors, see how this HEK293 cell line is optimized for suspension culture and viral vector production, which can significantly reduce costs.
CONTRACTS & ANALYTICAL
-
Control Strategies And Method Development For Nitrosamines In APIs And Drug Products
Explore regulatory insights, analytical strategies, and real-world case studies for effective nitrosamine control in APIs and drug products.
-
Sequencing Solutions For Nucleic Acids And Advanced Therapy Products
Leveraging an experienced partner's expertise in GMP-grade plasmid manufacturing and advanced analytical methods can accelerate the development and success of your next-generation therapies.
-
Inspiring Waves Of Change
Our comprehensive capabilities include the production of Active Pharmaceutical Ingredients (APIs), advanced intermediates, Cell and Gene Therapy technologies, registered starting materials, and analytical services.
-
Shedding Light On Photostability Forced Degradation
Ensure the stability and safety of your drug products by utilizing comprehensive forced degradation and photo-stability testing, guided by ICH and FDA standards, to identify degradation pathways and assess light exposure risks.
-
Stability And Storage Supported By Expert Scientists
Partner with SK pharmteco for reliable, ICH-compliant stability testing and storage solutions, supported by expert scientists and fully qualified chambers to ensure the safety and efficacy of your CGMP products.
-
Energy And Specialty Chemistry Solutions
Safely scale the production of APIs using highly energetic chemistry, backed by decades of expertise, controlled processes, and CGMP-compliant conditions from development to commercial manufacturing.
-
Stability And Storage Testing
Receive comprehensive stability testing solutions that ensure the safety, efficacy, and quality of your pharmaceutical products at every stage of development by partnering with us.
-
Nitrosamine Impurity And Control Testing
Get access to reliable testing services for the identification and quantification of impurities, ensuring product quality and maintaining patient confidence.
-
Control Strategies And Method Development For Nitrosamines In Peptide APIs And Drug Products
Pharmaceutical scientists and engineers must advance robust, sensitive, and efficient nitrosamine detection and control methods to ensure regulatory compliance and safeguard public health in peptide-based drugs.
-
Control Strategies And Method Development For Nitrosamines In APIs, Drug Products
Gain critical insights into nitrosamine control strategies, regulatory requirements, and advanced analytical methods to ensure compliance by August 2025.